|
|
|
Volumn 13, Issue 7, 2000, Pages 425-438
|
|
Ongoing progress in the Alzheimer's disease arena
a
a
PROUS SCIENCE
(Spain)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 [2 (1 BENZYL 4 PIPERIDINYL)ETHYL] 2,3 DIHYDRO 9 METHOXY 1H PYRROLO[3,4 B]QUINOLIN 1 ONE;
ALPHA TOCOPHEROL;
ALZHEIMER DISEASE VACCINE;
AMYLOID BETA PROTEIN;
ANAPHYLATOXIN;
ANSECULIN;
ANTHRACYCLINONE DERIVATIVE;
APOLIPOPROTEIN;
AXONYX;
CANDESARTAN HEXETIL;
CYANOCOBALAMIN;
CYCLOOXYGENASE 2 INHIBITOR;
CYMSERINE;
DONEPEZIL;
FOLIC ACID;
GALANTAMINE;
GINKGO BILOBA EXTRACT;
IBUPROFEN;
ISOCHROMAN DERIVATIVE;
L 962;
LETEPRINIM;
LETEPRINUM POTASSIUM;
MELATONIN;
MEMANTINE;
MEMORIN;
NCX 2216;
PHENSERINE;
PHYSOSTIGMINE;
PIFITHRIN ALPHA;
PIFITHRINE ALPHA;
PRESENILIN 1;
PRESENILIN 2;
PYRIDOXINE;
QUILOSTIGMINE;
RALOXIFENE;
RIVASTIGMINE;
SELEGILINE;
TACRINE;
THIAMINE;
UNCLASSIFIED DRUG;
ZANEPEZIL;
ADULT;
ALZHEIMER DISEASE;
CHOLINERGIC TRANSMISSION;
CLINICAL TRIAL;
CONFERENCE PAPER;
COST BENEFIT ANALYSIS;
DISEASE ASSOCIATION;
ECONOMIC ASPECT;
EPIDEMIOLOGICAL DATA;
HUMAN;
MAJOR CLINICAL STUDY;
NEUROFIBRILLARY TANGLE;
NEUROPROTECTION;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATHOPHYSIOLOGY;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RISK FACTOR;
SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;
SOCIAL ASPECT;
TREATMENT PLANNING;
|
|
EID: 0033667663
PISSN: 02140934
EISSN: None
Source Type: Journal
DOI: None Document Type: Conference Paper |
|
Times cited : (10)
|
|
References (0)
|
